Nanomedicine for Brain Delivery of Monoclonal Antibodies: The Impact of Nanocarrier Structure

Introduction: Monoclonal antibodies (mAbs) are potent therapeutics given its high specificity, prove of it is the increasing number of marketed mAbs [1,2]. Nanomedicine has emerged as a promising strategy for delivering biologics to the brain, particularly for overcoming the challenge of crossing the blood-brain barrier. However, ensuring effective mAb diffusion within brain tissue remains a critical hurdle. This study explores how nanomedicine can address this challenge by evaluating two nanosystems designed to enhance both brain diffusion and intracellular delivery of mAbs.